These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 21979296)

  • 21. Carboxypeptidase A3 (CPA3): a novel gene highly induced by histone deacetylase inhibitors during differentiation of prostate epithelial cancer cells.
    Huang H; Reed CP; Zhang JS; Shridhar V; Wang L; Smith DI
    Cancer Res; 1999 Jun; 59(12):2981-8. PubMed ID: 10383164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prostate cancer. Mortality and morbidity after non-curative treatment with aspects on diagnosis and treatment.
    Aus G
    Scand J Urol Nephrol Suppl; 1994; 167():1-41. PubMed ID: 7542397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Expression profile of prostate-specific antigen messenger RNA assessed by in situ hybridization is a novel prognostic marker for patients with untreated prostate cancer.
    Tsurusaki T; Koji T; Sakai H; Kanetake H; Saito Y
    Clin Cancer Res; 1998 Sep; 4(9):2187-94. PubMed ID: 9748138
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells.
    Abdul M; Hoosein N
    Anticancer Res; 2001; 21(3B):2045-8. PubMed ID: 11497296
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors.
    Gleave ME; Hsieh JT; Wu HC; von Eschenbach AC; Chung LW
    Cancer Res; 1992 Mar; 52(6):1598-605. PubMed ID: 1371718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.
    Chen CL; Sung J; Cohen M; Chowdhury WH; Sachs MD; Li Y; Lakshmanan Y; Yung BY; Lupold SE; Rodriguez R
    J Pharmacol Exp Ther; 2006 Nov; 319(2):533-42. PubMed ID: 16868035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanism of action of herbal supplement PC-SPES: elucidation of effects of individual herbs of PC-SPES on proliferation and prostate specific gene expression in androgen-dependent LNCaP cells.
    Hsieh TC; Wu JM
    Int J Oncol; 2002 Mar; 20(3):583-8. PubMed ID: 11836572
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.
    Olsson CA; de Vries GM; Raffo AJ; Benson MC; O'Toole K; Cao Y; Buttyan RE; Katz AE
    J Urol; 1996 May; 155(5):1557-62. PubMed ID: 8627821
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer.
    Gonzales JC; Fink LM; Goodman OB; Symanowski JT; Vogelzang NJ; Ward DC
    Clin Genitourin Cancer; 2011 Sep; 9(1):39-45. PubMed ID: 21723797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of baseline reverse transcriptase-PCR for prostate-specific antigen in men with hormone-refractory prostate cancer treated with chemotherapy.
    Ross RW; Manola J; Hennessy K; Galsky M; Scher H; Small E; Kelly WK; Kantoff PW
    Clin Cancer Res; 2005 Jul; 11(14):5195-8. PubMed ID: 16033836
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular staging of pelvic surgical margins after radical prostatectomy: comparison of RT-PCR for prostate-specific antigen and telomerase activity.
    Straub B; Müller M; Krause H; Goessl C; Schrader M; Heicappell R; Miller K
    Oncol Rep; 2002; 9(3):545-9. PubMed ID: 11956625
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Detection of circulating prostate specific antigen expressing prostatic cells in the bone marrow of radical prostatectomy patients by sensitive reverse transcriptase polymerase chain reaction.
    Gao CL; Dean RC; Pinto A; Mooneyhan R; Connelly RR; McLeod DG; Srivastava S; Moul JW
    J Urol; 1999 Apr; 161(4):1070-6. PubMed ID: 10081840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells.
    Frønsdal K; Saatcioglu F
    Prostate; 2005 Feb; 62(3):299-306. PubMed ID: 15389787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antiepileptic drugs with histone deacetylase inhibition activity and prostate cancer risk: a population-based case-control study.
    Salminen JK; Tammela TL; Auvinen A; Murtola TJ
    Cancer Causes Control; 2016 May; 27(5):637-45. PubMed ID: 27038166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of prostate specific antigen (PSA) is negatively regulated by p53.
    Gurova KV; Roklin OW; Krivokrysenko VI; Chumakov PM; Cohen MB; Feinstein E; Gudkov AV
    Oncogene; 2002 Jan; 21(1):153-7. PubMed ID: 11791186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy.
    Miller N; Smolkin ME; Bissonette E; Theodorescu D
    Cancer; 2005 Jun; 103(12):2499-506. PubMed ID: 15852361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of prostate-specific antigen expression by the junctional adhesion molecule A.
    Wang Q; Zheng JY; Kreth J; Yan X; Kamata M; Campbell RA; Xie Y; Chiu R; Berenson JR; Shi W; Chen IS; Pang S
    Urology; 2009 May; 73(5):1119-25. PubMed ID: 18602143
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype.
    Hobisch A; Ramoner R; Fuchs D; Godoy-Tundidor S; Bartsch G; Klocker H; Culig Z
    Clin Cancer Res; 2001 Sep; 7(9):2941-8. PubMed ID: 11555613
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Proteomic profiling of the effect of prostate-specific antigen on prostate cancer cells.
    Bindukumar B; Schwartz S; Aalinkeel R; Mahajan S; Lieberman A; Chadha K
    Prostate; 2008 Oct; 68(14):1531-45. PubMed ID: 18646040
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.